Abstract
Parkinsons disease (PD) is a common neurodegenerative disease, characterized by a selective loss of midbrain dopaminergic (DA) neurons. To address this problem, various types of stem cells that have potential to differentiate into DA neurons are being investigated as cellular therapies for PD, including cells derived from embryonic or adult donor tissue, and embryonic stem cells. These cell sources, however. have raised certain questions with regard to ethical and rejection issues. Recent progress in adult stems has further proved that the cells derived from adult tissue could be expanded and differentiated into DA precursor cells in vitro, and cell therapy with adult stem cells could produce a clear improvement for PD models. Using adult stem cells for clinic application may not only overcome the ethical problem inherent in using human fetal tissue or embryonic stem cells, but also open the possibility for autologous transplantation. The patient-specific adult stem cell is therefore a potential and prospective candidate for PD treatment.
Keywords: Parkinson's disease, dopaminergic neurons, adult stem cells, neural stem cells, induced pluripotent stem cells, embryonic stem cells, mesenchymal stem cells, carotid body stem cells, cell transplantation therapy, fetal stem cells, FOXA2
CNS & Neurological Disorders - Drug Targets
Title: Emerging Restorative Treatments for Parkinsons Disease: Manipulation and Inducement of Dopaminergic Neurons from Adult Stem Cells
Volume: 10 Issue: 4
Author(s): Junpeng Zhao and Qunyuan Xu
Affiliation:
Keywords: Parkinson's disease, dopaminergic neurons, adult stem cells, neural stem cells, induced pluripotent stem cells, embryonic stem cells, mesenchymal stem cells, carotid body stem cells, cell transplantation therapy, fetal stem cells, FOXA2
Abstract: Parkinsons disease (PD) is a common neurodegenerative disease, characterized by a selective loss of midbrain dopaminergic (DA) neurons. To address this problem, various types of stem cells that have potential to differentiate into DA neurons are being investigated as cellular therapies for PD, including cells derived from embryonic or adult donor tissue, and embryonic stem cells. These cell sources, however. have raised certain questions with regard to ethical and rejection issues. Recent progress in adult stems has further proved that the cells derived from adult tissue could be expanded and differentiated into DA precursor cells in vitro, and cell therapy with adult stem cells could produce a clear improvement for PD models. Using adult stem cells for clinic application may not only overcome the ethical problem inherent in using human fetal tissue or embryonic stem cells, but also open the possibility for autologous transplantation. The patient-specific adult stem cell is therefore a potential and prospective candidate for PD treatment.
Export Options
About this article
Cite this article as:
Zhao Junpeng and Xu Qunyuan, Emerging Restorative Treatments for Parkinsons Disease: Manipulation and Inducement of Dopaminergic Neurons from Adult Stem Cells, CNS & Neurological Disorders - Drug Targets 2011; 10 (4) . https://dx.doi.org/10.2174/187152711795563921
DOI https://dx.doi.org/10.2174/187152711795563921 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
Current Pharmaceutical Design Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Current Cancer Drug Targets Editorial
Recent Patents on Drug Delivery & Formulation Chronic Administration of an Aglycosylated Murine Antibody of Ponezumab Does Not Worsen Microhemorrhages in Aged Tg2576 Mice
Current Alzheimer Research Biomarkers as a Guide of Medical Treatment in Cardiovascular Diseases
Current Medicinal Chemistry The Brain-gut Axis-where are we now and how can we Modulate these Connections?
Current Neuropharmacology Disease-Modifying Agents in the Treatment of Multiple Sclerosis: A Review of Long-Term Outcomes
CNS & Neurological Disorders - Drug Targets Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Adenosine and Related Drugs in Brain Diseases: Present and Future in Clinical Trials
Current Topics in Medicinal Chemistry Magnetic Resonance-Based Metabolomics for Understanding Neurological Disorders: Current Status and Statistical Considerations
Current Metabolomics Glycyrrhizic Acid Ameliorates Cognitive Impairment in a Rat Model of Vascular Dementia Associated with Oxidative Damage and Inhibition of Voltage-Gated Sodium Channels
CNS & Neurological Disorders - Drug Targets The Use of Microarrays to Study Childhood Developmental Brain Disorders
Current Genomics Multiple Drug Targets in the Management of Type 2 Diabetes
Current Drug Targets Lactones: Generic Inhibitors of Enzymes?
Mini-Reviews in Medicinal Chemistry Astrocyte Influences on Ischemic Neuronal Death
Current Molecular Medicine Aryltetralin-type Lignan of Podophyllum: A Comprehensive Review
The Natural Products Journal Hematoma Expansion Following Intracerebral Hemorrhage: Mechanisms Targeting the Coagulation Cascade and Platelet Activation
Current Drug Targets Gene Patents in the Primary Prevention of Vascular Diseases
Recent Patents on DNA & Gene Sequences Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry ERM Complex, A Therapeutic Target for Vascular Leakage Induced by Diabetes
Current Medicinal Chemistry